Quanta

Quanta System on the Peaks of the Urological Laser World Once Again: Quanta Magneto Technology™

Retrieved on: 
Friday, April 5, 2024
Health, Medical Devices, Surgery, General Health, Research, Science, Biotechnology, Quanta, Sorbonne University, Lithotripsy, Magneto, Holmium, History, Prostate, EAU, Surgeon, Safety, Cancer, Multimedia, Computer data storage

View the full release here: https://www.businesswire.com/news/home/20240404169544/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240404169544/en/
    Cyber Ho Magneto with Quanta Magneto Technology™ (Photo: Business Wire)
    On the way to its 40th anniversary Quanta System remains steadfast in its mission: innovate to improve the lives of people around the world; with an unwavering belief that progress is always possible.
  • The global leader in laser technologies continually collaborates with medical professionals, working side by side with doctors to advance healthcare.
  • It is this commitment that drives the latest groundbreaking addition to the Cyber Ho family: Cyber Ho Magneto.
  • Cyber Ho Magneto, in fact, is the first laser system that tamed the peak power of holmium, turning it into a much longer pulse duration providing the superior dusting of a Thulium Fiber Laser.

New MLPerf Inference Benchmark Results Highlight The Rapid Growth of Generative AI Models

Retrieved on: 
Wednesday, March 27, 2024
Data Management, Security, Technology, Software, Networks, Artificial Intelligence, Internet, Quanta, Cloud, Hewlett Packard Enterprise, Intel, Synthetic media, Azure, Organization, Acceleration, Qualcomm, Red Hat, Meta, Running, AI, Fujitsu, LLM, Cisco, Quanta Cloud Technology, Dell, Medical device

The MLPerf Inference benchmark suite, which encompasses both data center and edge systems, is designed to measure how quickly hardware systems can run AI and ML models in a variety of deployment scenarios.

Key Points: 
  • The MLPerf Inference benchmark suite, which encompasses both data center and edge systems, is designed to measure how quickly hardware systems can run AI and ML models in a variety of deployment scenarios.
  • We are thrilled to collaborate with Meta to bring Llama 2 70B to the MLPerf Inference v4.0 benchmark suite.
  • "Generative AI use-cases are front and center in our v4.0 submission round,” said Mitchelle Rasquinha, co-chair of the MLPerf Inference working group.
  • “The v4.0 release of MLPerf Inference represents a full embrace of generative AI within the benchmark suite,” said Miro Hodak, MLPerf Inference co-chair.

China Medical University Hospital (CMUH) Developing iDREAM to Detect Sleep Apnea at Home

Retrieved on: 
Saturday, March 30, 2024
Quanta, Cloud, Diagnosis, Sleep, UPPP, Sleep apnea, Certification, Sudden death, Intracerebral hemorrhage, Otorhinolaryngology, Patient, Heart rate, Stroke, Research, AI, Record, Snoring, Society, OSAS, Hospital, Electroencephalography, Automation, Hypertension, Respiratory system, Family, Food, Physician, ECG, Apnea, Pharmaceutical industry

TAICHUNG, March 30, 2024 /PRNewswire/ -- Snoring can be an alarming sign of obstructive sleep apnea syndrome (OSAS). Studies showed that 50% of individuals who snore may experience sleep apnea, which can lead to life-threatening conditions such as heart disease, hypertension, intracerebral hemorrhage, stroke, and even sudden death during night-time in severe cases. Sleep Medicine Center at China Medical University Hospital (CMUH, Taiwan) has introduced iDREAM (Intelligent Detection of Respiratory Events through Automated Monitoring), incorporating Quanta's QOCA Portable ECG Monitoring Device, as a simple solution to efficiently detect symptoms of apnea patients during their sleep at home. More than 100 patients have been in clinical trials of iDREAM. With this AI-powered ECG analysis, CMUH's physicians are able to identify obstructive sleep apnea syndrome (OSAS) more accurately and to reduce the time spent for diagnosis and treatment.

Key Points: 
  • Sleep Medicine Center at China Medical University Hospital (CMUH, Taiwan) has introduced iDREAM (Intelligent Detection of Respiratory Events through Automated Monitoring), incorporating Quanta's QOCA Portable ECG Monitoring Device, as a simple solution to efficiently detect symptoms of apnea patients during their sleep at home.
  • With this AI-powered ECG analysis, CMUH's physicians are able to identify obstructive sleep apnea syndrome (OSAS) more accurately and to reduce the time spent for diagnosis and treatment.
  • iDREAM , the home-based sleep detection system, detects ECG change from OSAS episodes and determines severity using its deep learning methodology.
  • It demonstrates 92.7% and 93.2% accuracy for sleep apnea and wake-up events (interruption of sleep from apnea), and 95.8% accuracy for defining severe OSAS (30 episodes per hour).

Nvidia CEO reiterates solid partnership with TSMC

Retrieved on: 
Friday, March 22, 2024
Quanta, Cloud, Microsoft, Azure, Microsoft Azure, GTC, Series, Foxconn, GPU, Learning, CUDA, H100, AI, TSMC, GCT, A10, Samsung, Quanta Cloud Technology, Pegatron, Multimedia, Semiconductor

Speaking to the press later, Huang said Nvidia will have a very strong demand for CoWoS, the advanced packaging services TSMC offers.

Key Points: 
  • Speaking to the press later, Huang said Nvidia will have a very strong demand for CoWoS, the advanced packaging services TSMC offers.
  • He said the company is embarking on a new journey and will work closely with TSMC.
  • A major reason for the shortages of Nvidia's AI chips is insufficient CoWoS support from TSMC.
  • Huang admitted that the way Nvidia is working for its partners and the AI industry is like the way TSMC is making chips for Nvidia.

Synthace Announces Appointment of Willem Baralt as New Chairman

Retrieved on: 
Wednesday, March 20, 2024
Quanta, Automation, Growth, History, IPO, Doctor of Philosophy, Sofinnova, FDA, Fine chemical

LONDON and BOSTON, March 20, 2024 /PRNewswire/ -- Synthace , the leading digital experiment platform for life science R&D, today announced the appointment of Willem Baralt as its new Chairman of the Board.

Key Points: 
  • LONDON and BOSTON, March 20, 2024 /PRNewswire/ -- Synthace , the leading digital experiment platform for life science R&D, today announced the appointment of Willem Baralt as its new Chairman of the Board.
  • Mr. Baralt joined the company in February 2024 during a period of accelerating growth, as Synthace expands its offerings.
  • "I am thrilled to welcome Willem aboard," said Guy Levy-Yurista, PhD, CEO of Synthace.
  • "We welcome Willem Baralt's appointment as Chairman of the Board," said Joe Anderson, PhD, Partner at Sofinnova Partners.

Synthace Announces Appointment of Willem Baralt as New Chairman

Retrieved on: 
Wednesday, March 20, 2024
Quanta, Automation, Growth, History, IPO, Doctor of Philosophy, Sofinnova, FDA, Fine chemical

LONDON and BOSTON, March 20, 2024 /PRNewswire/ -- Synthace , the leading digital experiment platform for life science R&D, today announced the appointment of Willem Baralt as its new Chairman of the Board.

Key Points: 
  • LONDON and BOSTON, March 20, 2024 /PRNewswire/ -- Synthace , the leading digital experiment platform for life science R&D, today announced the appointment of Willem Baralt as its new Chairman of the Board.
  • Mr. Baralt joined the company in February 2024 during a period of accelerating growth, as Synthace expands its offerings.
  • "I am thrilled to welcome Willem aboard," said Guy Levy-Yurista, PhD, CEO of Synthace.
  • "We welcome Willem Baralt's appointment as Chairman of the Board," said Joe Anderson, PhD, Partner at Sofinnova Partners.

EQS-News: TRATON very successful in 2023: sales revenue up to around €47 billion, earnings per share more than doubled

Retrieved on: 
Wednesday, March 13, 2024
Quanta, CFO, Quanta Services, CHRO, Transport, Growth, Navistar, Volkswagen Caminhões e Ônibus, Annual, Partnership

TRATON very successful in 2023: sales revenue up to around €47 billion, earnings per share more than doubled

Key Points: 
  • TRATON very successful in 2023: sales revenue up to around €47 billion, earnings per share more than doubled
    The issuer is solely responsible for the content of this announcement.
  • TRATON very successful in 2023: sales revenue up to around €47 billion, earnings per share more than doubled
    Munich, March 5, 2024 – The TRATON GROUP grew its sales revenue by 16% to €46.9 billion (2022: €40.3 billion) in 2023.
  • For the TRATON GROUP, being successful also means driving the transition to a world of sustainable transportation.
  • Despite the resulting decline in sales revenue, Volkswagen Truck & Bus managed to record an adjusted operating return on sales of 8.8%.

Quanta Therapeutics Announces Late-Breaking Presentation of QTX3544, a G12V-preferring multi-KRAS inhibitor, at AACR Annual Meeting

Retrieved on: 
Tuesday, March 5, 2024
Quanta, SAN, Therapy, AACR, Discovery, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Quanta Therapeutics, a privately-held biopharmaceutical company pioneering targeted therapies to treat RAS-driven cancers, today announced it will give a late-breaking poster presentation of QTX3544 at the American Association for Cancer Research (AACR) Annual Meeting being held April 5-10, 2024, in San Diego, California.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Quanta Therapeutics, a privately-held biopharmaceutical company pioneering targeted therapies to treat RAS-driven cancers, today announced it will give a late-breaking poster presentation of QTX3544 at the American Association for Cancer Research (AACR) Annual Meeting being held April 5-10, 2024, in San Diego, California.
  • QTX3544 is a KRASG12V-preferring multi-KRAS inhibitor with favorable preclinical properties, including potency, selectivity, and oral bioavailability.
  • Quanta Therapeutics' allosteric approach has the potential to target the majority of KRAS mutations with a robust mechanism of action addressing multiple conformations of KRAS.
  • Title: Discovery and characterization of QTX3544, a potent, selective, and orally bioavailable allosteric G12V-preferring multi-KRAS inhibitor

Fibocom Collaborates with Industry Partners to Accelerate 5G RedCap Commercialization in Extended Markets

Retrieved on: 
Tuesday, February 27, 2024
Quanta, ODU, CPE, Partnership, MWC, Quanta Computer, Redcap, Communication, 3GPP, PLANET, Dongle, Internet, Mobile World Congress, Mobile phone

BARCELONA, Spain, Feb. 27, 2024 /PRNewswire/ -- Fibocom (Stock code: 300638), a global leading provider of IoT (Internet of Things) wireless solutions and wireless communication modules, is delighted to announce an industry-leading momentum of implementing deployable and commercialized 5G RedCap module solution to 5G IoT scenarios, in collaboration with well-known customers including but not limited to Askey, Quanta Computer, PLANET, companies of whom have profound influence in the vertical markets respectively. Rigorous engineering testing and verification has been conducted to ensure the seamless integration of the latest generation 5G RedCap on customers' devices. Enabling ultra-reliable data transmission and efficient network utilization under the 5G network catering to diverse application scenarios such as in-home connectivity, enterprises-level connectivity, and industrial-grade connectivity, etc.

Key Points: 
  • By achieving momentum across industries, the 5G RedCap module solution that Fibocom offers is capable of delivering a high-performance and cost-effective connectivity service for industry customers at the early stage of the 5G RedCap rollout.
  • Fibocom 5G RedCap module solution provides enhanced network performance, simplified hardware and antenna design while conserving low power consumption.
  • "We are proud of the joint announcement of the commercially deployable 5G RedCap solution with our customers from diversified markets based on Fibocom's 5G RedCap module portfolios.
  • "We look forward to unleashing the full potential of 5G RedCap with our industry customers and helping customers to realize the monetization of 5G RedCap with less time to market."

At MWC Barcelona 2024, O-RAN ALLIANCE Participants Showcase Advanced Solutions to Improve RAN Performance

Retrieved on: 
Thursday, February 15, 2024
Quanta, Cloud, Economics, Fujitsu, Broadcom Inc., Quanta Cloud Technology, Intel, TCO, Spirent, Samsung, Exhibition, RAN, Keysight, Viettel, Rohde & Schwarz, National University of Singapore, Certification, ITRI, Total cost of ownership, Total cost, Viavi Solutions, Ericsson, AMD, Automation, Map, LitePoint, AT&T, Anritsu, VMware, CommScope, HCLTech, WNC, RIC, EURECOM, Mobile World Congress, Rail transport

O-RAN's open architecture enables partnerships; encourages innovation by leveraging know-how

Key Points: 
  • O-RAN's open architecture enables partnerships; encourages innovation by leveraging know-how
    The showcased intelligent RAN solutions demonstrate capabilities aiming to improve the RAN performance in traffic steering, energy savings, service quality, spectrum efficiency and network management.
  • Examples include machine learning models for network load balancing, orchestrating applications' requests for network resources, and private network management.
  • O-RAN ALLIANCE plans to publish an interactive map of O-RAN demos at MWC to allow easy navigation to the demos at the exhibition.
  • O-RAN ALLIANCE will hold its O-RAN ALLIANCE Summit on Wednesday, 28 February 2024 from 8:30 to 13:00 CET in MWC hall 8, theatre 5, and also online.